Jeff Bockman explains the importance of attending Cancer Progress 2021 and participating in partnering in his video below. Check it out to get a clearer picture of what to expect at Cancer Progress 2021.

This session will focus on perhaps the most active area of drug development in Oncology: the effort to improve upon outcomes with checkpoint inhibitors (CPI) by combining agents post failure of the checkpoint with the CPI to resensitize the tumor microenvironment and enable patients to continue to derive benefit from immunotherapies. A diverse array of MOAs and therapeutic approaches are being harnessed to try to address this daunting task, ranging from new checkpoint inhibitors, costims and multifunctional biologics, to agents targeting other “bad actors’ and pathways in the TME including modulators of innate immunity. In addition, oncolytic viruses, agents driving immunogenic cell death, cancer vaccines and cell therapies are also looking to provide value in this checkpoint-experienced space. Finally, an alternative approach, but one requiring more wherewithal (financially and in time) is to bring such new agents forward into combination with checkpoint right at the start, into upfront settings.

Cancer Progress by Cello Health
25-B Hanover Road, Suite 320
Florham Park, NJ 07932
Eileen Tuma, Conference Organizer
cellohealthbioconsulting.com | cancerprogress.live | cellohealth.com